Moody Aldrich Partners LLC Sells 15,506 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Moody Aldrich Partners LLC reduced its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 25.6% in the 4th quarter, Holdings Channel reports. The firm owned 45,138 shares of the company’s stock after selling 15,506 shares during the period. Moody Aldrich Partners LLC’s holdings in Axsome Therapeutics were worth $3,819,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. KBC Group NV increased its holdings in Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after purchasing an additional 385 shares during the period. Janney Montgomery Scott LLC lifted its position in Axsome Therapeutics by 90.9% in the 4th quarter. Janney Montgomery Scott LLC now owns 13,745 shares of the company’s stock valued at $1,163,000 after acquiring an additional 6,546 shares in the last quarter. Flower City Capital bought a new position in Axsome Therapeutics in the 4th quarter valued at about $254,000. Pallas Capital Advisors LLC bought a new position in Axsome Therapeutics in the 4th quarter valued at about $2,237,000. Finally, JPMorgan Chase & Co. increased its stake in Axsome Therapeutics by 14.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock valued at $19,062,000 after buying an additional 27,534 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Stock Performance

Shares of NASDAQ AXSM opened at $102.46 on Wednesday. The firm has a 50 day moving average of $92.99 and a 200 day moving average of $90.41. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The firm has a market capitalization of $4.97 billion, a price-to-earnings ratio of -15.69 and a beta of 1.04. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $105.64.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The business had revenue of $104.76 million for the quarter, compared to the consensus estimate of $98.71 million. During the same quarter in the previous year, the firm earned ($1.32) earnings per share. On average, research analysts anticipate that Axsome Therapeutics, Inc. will post -4.73 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on AXSM shares. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a research note on Friday, January 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $121.00 price objective on shares of Axsome Therapeutics in a report on Thursday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 price objective on shares of Axsome Therapeutics in a report on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $180.00 price target on shares of Axsome Therapeutics in a report on Tuesday, January 21st. Finally, Royal Bank of Canada raised their price target on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the company an “outperform” rating in a report on Friday, October 4th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $130.69.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.